Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference
Yahoo/BusinessWire
Saturday, February 12, 2011 - 12:55pm
tags:
Human Genome Sciences
Biotech Optimists Throw In the Towel
Motley Fool
Saturday, February 12, 2011 - 12:55pm
tags:
biotech, MannKind, Orexigen, Arena Pharmaceuticals, XenoPort, A.P. Pharma
iBio: Risky, But Early Stage Pipeline Potentially Offers Long-Term Reward
Seeking Alpha
Saturday, February 12, 2011 - 12:53pm
tags:
iBio, biosimilars
Axcan completes buyout of Eurand
Yahoo/AP
Saturday, February 12, 2011 - 12:52pm
tags:
Aptalis
Genentech's Lucentis does well in study of diabetic eye condition Read more: Genentech's Lucentis does well in study of diabetic eye condition
bizjournals.com
Saturday, February 12, 2011 - 12:21pm
tags:
Lucentis, Genentech, diabetic macular edema, diabetes
Two ETFs for the Boom in Big Pharma
Seeking Alpha
Saturday, February 12, 2011 - 12:20pm
tags:
Big Pharma
Lilly CEO Criticizes Pace of R&D
Seeking Alpha
Saturday, February 12, 2011 - 12:19pm
tags:
Eli Lilly
Is Pfizer the Right Stock to Retire With?
Motley Fool
Saturday, February 12, 2011 - 12:18pm
tags:
Pfizer
MannKind Shares Plunged: What You Need to Know
Motley Fool
Saturday, February 12, 2011 - 12:18pm
tags:
MannKind, Afrezza, inhaled insulin, diabetes
Merck: Time to Buy a Rewarding, Long-Term Investment?
Seeking Alpha
Saturday, February 12, 2011 - 12:17pm
tags:
Merck
FDA Meeting Should Clarify Path for Neurocrine Bio's Efforts
Seeking Alpha
Saturday, February 12, 2011 - 12:16pm
tags:
Neurocrine, Abbott Laboratories, endometriosis, Elagolix, Lupron
Analysts reassess Merck-Schering merger
Fierce Pharma
Friday, February 11, 2011 - 12:20pm
tags:
Merck, Schering Plough, M&A
Opko Health seeks $250M offering
Bizjournals.com
Friday, February 11, 2011 - 12:19pm
tags:
OPKO Health, stock offering
FDA Meeting Should Clarify Path For Neurocrine Bio's Efforts
Seeking Alpha
Friday, February 11, 2011 - 12:18pm
tags:
FDA, Neurocrine, Abbott Laboratories
The Silver Lining to Idenix's Bad News
Minyanville
Friday, February 11, 2011 - 12:17pm
tags:
Idenix, GSK, HIV
Drug Firms Must Swallow Bitter Pill
WSJ Online
Friday, February 11, 2011 - 12:16pm
tags:
Big Pharma, innovation, R&D
Some Drugmakers Hold Talks With The Patent Pool
Pharmalot
Friday, February 11, 2011 - 12:09pm
tags:
patents, HIV, Gilead Sciences, Sequoia, ViiV Healthcare, GSK, Pfizer, Medicines Patent Pool
Neurocrine rises to 4Q profit on licensing fees
Yahoo/AP
Friday, February 11, 2011 - 12:04pm
tags:
Neurocrine, earnings
Cephalon 4Q profit falls on costs
Yahoo/AP
Friday, February 11, 2011 - 12:03pm
tags:
Cephalon, earnings
Warner Chilcott Put-Options Volume Surges to Three-Month High
Bloomberg
Friday, February 11, 2011 - 12:01pm
tags:
Warner Chilcott

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.